The 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held in Houston, Texas, on Nov. 6–10, 2024. This conference dispatch summarizes the following themes from the meeting: 

• Microbiome: Ready for prime time? — Covering presentations from Arielle Elkrief (University of Montreal Research Center, Canada), Anne-Laure Mallard de la Varende (Gustave Roussy, France) and Urvi A. Shah (Memorial Sloan Kettering Cancer Center, US).
• Solid tumor immune-oncology at the tipping point — Covering presentations from Jo Brewer (Adaptimmune), Pablo Martinez (Amgen) and Jim Rotolo (Sapience Therapeutics).
• Advances in lung cancer — Covering presentations from Jacob Sands (Dana-Farber Cancer Institute, US), Victor Zaporojan (MAIA Biotechnology, Inc.), Solange Peters (Lausanne University, Switzerland) and Alex Chen (National Cancer Institute, US).
• Presidential session — Covering presentations from Ecaterina E. Dumbrava (University of Texas MD Anderson Cancer Center, US), Hieu M. Ta (Cleveland Clinic Foundation, US), Catherine Phelps (University of Pittsburgh School of Medicine, US) and Tatiana Delgado Cruz (Weill Cornell Medical College, US).
• Pipeline therapies and ICI trials of interest — Covering presentations from Michael Wong (University of Texas MD Anderson Cancer Center, US), Roger Li (Moffitt Cancer Center, US), David Hsieh (University of Texas Southwestern, US) and Melissa Johnson (Sarah Cannon Research Institute, UK).
• CAR-T versus bispecifics — Covering presentation from Jason Westin (University of Texas MD Anderson Cancer Center, US).
• Novel targets and biomarkers — Covering presentations from Xiaole Liu (GV20 Therapeutics) and Douglas Johnson (Vanderbilt University Medical Center, US).

To view the full report, select Download Report PDF at the top of this page.